Related Experiment Video
Updated: Feb 17, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
938
SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis
Hanguang Hu1,2, Wen Cai1,2, Shu Zheng2
1Department of Medical Oncology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Summary
Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) expression is linked to better outcomes in gastrointestinal cancers. This meta-analysis suggests SPARCL1 may serve as a valuable prognostic marker for these malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) exhibits altered expression in gastrointestinal (GI) cancers.
- The prognostic significance of SPARCL1 in GI malignancies is not well-established.
Purpose of the Study:
- To conduct a meta-analysis evaluating SPARCL1 as a prognostic marker in GI malignancies.
- To explore the association between SPARCL1 expression and clinicopathological features in GI cancers.
Main Methods:
- Systematic literature search across multiple databases (PubMed, Embase, EBSCO, CNKI, Wanfang).
- Pooled analysis of hazard ratios (HRs) and odds ratios (ORs) using random-effects or fix-effects models.
- Assessment of heterogeneity and publication bias.
Main Results:
- Analysis of 8 studies with 2,356 patients indicated that higher SPARCL1 expression correlates with improved prognosis (HR=0.57).
- SPARCL1 expression is associated with reduced distant metastasis (OR=0.44) and lymph node metastasis (OR=0.56), and altered tumor differentiation (OR=2.21).
- Subgroup analyses revealed no impact on lymph node metastasis in colorectal cancer or tumor differentiation in gastric cancer; no publication bias was detected.
Conclusions:
- SPARCL1 shows potential as a novel prognostic predictive factor for GI malignancies.
- SPARCL1 expression may influence the clinicopathological characteristics of GI cancers.
- Further large-scale studies and mechanistic investigations are warranted to confirm SPARCL1's prognostic value.
